Home / Business and Economy / Genmab Soars: 2026 Revenue Outlook Skyrockets
Genmab Soars: 2026 Revenue Outlook Skyrockets
27 Aug
Summary
- Genmab raised 2026 revenue forecast to $4.325-$4.525 billion.
- First-half revenue grew 25% to $2,051 million, driven by DARZALEX and EPKINLY.
- Hedge fund interest in Genmab surged in Q1 2026, with major increases in holdings.
Genmab A/S has raised its full-year 2026 revenue guidance to between $4.325 billion and $4.525 billion. This upward revision surpasses the company's previous outlook and highlights strong commercial performance across its royalty streams and proprietary portfolio.
In the first half of 2026, Genmab reported total revenue of $2,051 million, marking a 25% increase compared to the prior year. Royalty revenue grew by 24% to $1,708 million, primarily due to substantial net sales of DARZALEX. Furthermore, global net sales for EPKINLY/TEPKINLY experienced a significant surge of 48%, reaching $312 million.
Operating profit for the first half of 2026 stood at $555 million, with adjusted operating profit rising 18% to $656 million. Despite these positive results, operating expenses increased by 28% due to pipeline investments. Analysts maintain a positive outlook, with Guggenheim recently raising Genmab's price target.
Hedge fund sentiment towards Genmab has become notably more optimistic. The number of hedge funds holding positions increased from 24 in Q4 2025 to 30 in Q1 2026. Significant institutional investors like Paradigm Biocapital Advisors and Orbis Investment Management have substantially increased their stakes.
